Previously, we reported that a new genetically diverse CCR5 (R5) tropic simian/human immunodeficiency virus (SHIV-MK38) adapted to rhesus monkeys became more neutralization resistant to SHIV-infected plasma than did the parental SHIV-KS661 clone. Here, to clarify the significance of the neutralization-resistant phenotype of SHIV in a macaque model, we initially investigated the precise neutralization phenotype of the SHIVs, including SHIV-MK38 molecular clones, using SHIV-MK38-infected plasma, a pooled plasma of human immunodeficiency virus (HIV)-infected individuals, soluble CD4 and anti-HIV-1 neutralizing mAbs, the epitopes of which were known. The results show that SHIV-KS661 had tier 1 neutralization sensitivity, but monkeyadapted R5 tropic SHIV-MK38 acquired neutralization resistance similar to that of tier 2 or 3 as a clone virus. Sequence analysis of the env gene suggested that the neutralization-resistant phenotype of SHIV-MK38 was acquired by conformational changes in Env associated with the net charge and potential N-linked glycosylation sites. To examine the relationship between neutralization phenotype and stably persistent infection in monkeys, we performed in vivo rectal inoculation experiments using a SHIV-MK38 molecular clone. The results showed that one of three rhesus monkeys exhibited durable infection with a plasma viral load of 10 5 copies ml 21 despite the high antibody responses that occurred in the host. Whilst further improvements are required in the development of a challenge virus, it will be useful to generate a neutralizationresistant R5 tropic molecular clone of the SHIV-89.6 lineage commonly used for vaccine development -a result that can be used to explore the foundation of AIDS pathogenesis.
INTRODUCTION
Simian immunodeficiency virus (SIV)/macaque models of AIDS play important roles as surrogates of human immunodeficiency virus type 1 (HIV-1) in understanding AIDS pathogenesis and in vaccine development. Although SIV is an excellent model of HIV-1, homology of the env gene between SIV and HIV-1 is low (Yuste et al., 2006) , and consequently reciprocal neutralizing antibodies do not show cross-reactivity (Javaherian et al., 1992) . Thus, an important limitation of the SIV/macaque model is that the protective effects of neutralizing antibodies against HIV-1 cannot be examined. Therefore, simian/ human immunodeficiency viruses (SHIVs) constructed by inserting HIV-1 env, tat, vpu and rev into the SIV backbone have been developed to carry the antigenicity of HIV-1 Env into SIV (Shibata et al., 1991) . Highly pathogenic SHIVs, which persistently infected rhesus macaques with a high set point following a high viral load peak, were obtained using in vivo adaptation to macaques (Reimann et al., 1996; Shinohara et al., 1999) . As highly pathogenic SHIVs are useful in evaluating anti-HIV-1 neutralizing antibodies, SHIV-infected macaque models have been used in many preclinical investigations, even though SHIVs can also be used to evaluate cytotoxic Based on the Env features described above, to improve previously used SHIVs, we focused on two differences between HIV-1 initial clinical isolates and previously used SHIVs. The first difference is the co-receptor tropism of the viruses. Most highly pathogenic SHIVs predominantly use CXCR4 (X4) as a co-receptor and preferentially infect naive CD4 + T-lymphocytes, which highly express CXCR4 (Mehandru, 2007) . Highly pathogenic SHIVs deplete CD4
+ T-lymphocytes in peripheral blood with a rapid reduction in a few weeks, which quickly results in AIDS (Sadjadpour et al., 2004; Reimann et al., 2005; Fukazawa et al., 2008) . However, HIV-1 initial clinical isolates and SIVs use CCR5 (R5) as a co-receptor. They preferentially infect memory CD4 + T-lymphocytes, which highly express CCR5 (Mehandru, 2007) and rapidly decrease CD4 + T-lymphocytes in effector sites such as the intestine, whilst they cause gradual loss of naive CD4 + T-lymphocytes in peripheral blood (Veazey et al., 1998; Mehandru, 2007; Wang et al., 2007) . The second difference is the level of neutralization sensitivity. As reported previously, HIV-1 primary isolates are relatively resistant against anti-HIV-1 neutralizing antibodies compared with T-cell-line-adapted laboratory strains (Moore et al., 1995) . Based on these results, most previously used SHIVs were thought to be neutralization sensitive because they contained the env gene of laboratory strains obtained by passaging through T-cell lines. Another report showed that the neutralization phenotype against neutralizing antibodies can be categorized as: tier 1 (neutralization sensitive), tier 2 (neutralization resistant) and tier 3 (extremely neutralization resistant) (Seaman et al., 2010) . The majority of HIV-1 clinical isolates are categorized as tier 2, whilst HIV-1 laboratory strains are categorized as tier 1. Therefore, it is important to generate a challenge virus with greater than tier 2 neutralization resistance to evaluate its protective effect on vaccine candidates.
As described above, we focused on co-receptor use and the neutralization phenotype of the virus, and attempted to improve a previously used SHIV. We selected the SHIV-89.6 lineage as a parental strain because SHIV-89.6P, a derivative of SHIV-89.6, has been used most widely for the development of vaccines and therapeutic interventions. We reasoned that generation of neutralization-resistant R5 tropic SHIV derived from SHIV-89.6 would be valuable with regard to comparing data between the virus and SHIV-89.6P. Hence, we generated SHIV-MK38 from SHIV-KS661, a derivative of SHIV-89.6, by introducing five amino acid substitutions in the V3 region to alter co-receptor use and two in vivo passages to adapt the virus to rhesus monkeys (Shinohara et al., 1999; Matsuda et al., 2010) . SHIV-MK38 is R5 tropic and highly competent in replicating in rhesus macaques, and becomes neutralization resistant to autologous plasma in these SHIV-infected monkeys compared with the original SHIV-KS661 and SHIV-MK1, which are both the R5 virus prior to acclimation to monkeys . However, SHIV-MK38 acquires genetic diversity by accumulating mutations during in vivo passages and the precise nature of its neutralization resistance remains unclear. Here, we generated a molecular clone of SHIV-MK38, and examined its neutralization phenotype and infectivity in rhesus monkeys.
RESULTS

Generation of SHIV-MK38 infectious molecular clones
To examine the precise nature of neutralization resistance in the SHIV-MK38 strain, we generated molecular clones of SHIV-MK38. A virus neutralization phenotype is determined based on membrane-external regions of the Env protein. Therefore, viral RNA of SHIV-MK38 was extracted and its env gene was amplified by PCR following cDNA synthesis. The amplified env fragments were replaced with the equivalent region of the original SHIV-KS661 using restriction enzyme sites Sph I and Xho I (Fig. 1) . Six infectious molecular clones of SHIV-MK38 were obtained by cloning, and named MK38#811, MK38#812, MK38#813, MK38#814, MK38#816 and MK38#818.
Neutralization analysis of SHIV-MK38 and SHIV-MK38 molecular clones
To explore whether the six molecular clones reflected the neutralization phenotype of SHIV-MK38, we performed a neutralization assay using plasma from a SHIV-MK38-infected monkey at 16 weeks post-inoculation (p.i.) (Fig. 2a) . Matsuda et al. (2010) previously reported that the plasma neutralized SHIV-KS661 and SHIV-MK1, but did not neutralize SHIV-MK38. Whilst SHIV-KS661 and SHIV-MK1 were neutralized by the plasma and their infectivity decreased to v22 %, SHIV-MK38 was not neutralized at all in the presence of the plasma, consistent with previous data indicating that SHIV-MK38 was neutralization resistant. In the six molecular clones, MK38#814 and MK38#818 infection was not inhibited by the plasma, and infectivity reached 114 and 175 %, respectively, suggesting that MK38#814 and MK38#818 clones, like the parental SHIV-MK38 strain, were neutralization resistant. The infectivity values of the other molecular clones (MK38#811, MK38#812, MK38#813 and MK38#816) were 6.4, 4.2, 0.41 and 6.2 %, respectively. Therefore, of the six molecular clones, MK38#814 and MK38#818 were neutralization resistant against autologous plasma from SHIV-MK38-infected monkeys, similar to the parental SHIV-MK38 strain.
To investigate whether the neutralization-resistant property of SHIV-MK38, MK38#814 and MK38#818 represented strain-specific resistance or strain-independent general resistance, a neutralization assay was performed using pooled plasma from HIV-1-infected individuals (Fig. 2b) . We found that the 50 % inhibition dilution (ID 50 ) of HIV-1 reference clone 6535.3 (categorized as tier 1) was 1 : 433, whilst that of PVO.4 (categorized as tier 3) was 1 : 112. The ID 50 values of SHIV-KS661 and SHIV-MK1 were 1 : 437 and 1 : 353, respectively, and closer to 6535.3. However, the ID 50 values of SHIV-MK38 and MK38#818 were 1 : 159 and 1 : 98, respectively, and closer to PVO.4. The ID 50 of SHIV-MK#814 was 1 : 267, representing an intermediate value.
Next, we performed a neutralization assay against anti-HIV-1 neutralizing mAbs, the epitopes of which were known, and also soluble CD4 (sCD4) (Fig. 2c) . We used three types of anti-HIV-1 neutralizing mAb: KD-247 (which recognizes GPGR in the V3 region), and 4E10 and 2F5 (which recognize NWFDIT and ELDKWA, respectively, in the conserved MPER of gp41) (Purtscher et al., 1994; Stiegler et al., 2001; Eda et al., 2006) . Whilst the 50 % inhibition concentration (IC 50 ) of SHIV-KS661 against KD-247 was 0.59 mg ml
21
, the IC 50 values of SHIV-MK38, MK38#814 and MK38#818 were w50 mg ml
, suggesting that SHIV-MK38, MK38#814 and MK38#818 showed *100 times greater neutralization resistance to KD-247 than did SHIV-KS661. The IC 50 of PVO.4 against KD-247 was w50 mg ml
. The data showed that SHIV-MK38, MK38#814 and MK38#818 had levels of neutralization resistance against KD-247 that were comparable to that of PVO.4. Next, the IC 50 values of SHIV-MK38, MK38#814, MK38#818 and PVO.4 against 4E10 were found to be 37.2, 2.19, 9.27 and 9.51 mg ml
, respectively, whilst that of SHIV-KS661 was 0.51 mg ml
, which showed that SHIV-MK38 and MK38#818 had w18 times greater neutralization resistance to 4E10 than did SHIV-KS661. However, compared with PVO.4, SHIV-MK38 showed about four times greater neutralization resistance to 4E10, but the neutralization resistance of MK38#818 was equivalent to that of PVO.4. The IC 50 values of SHIV-MK38, MK38#814, MK38#818 and PVO.4 against 2F5 were 36.6, 2.03, 7.64 and w50 mg ml
, respectively, whilst that of SHIV-KS661 was 1.00 mg ml
. The data indicate that SHIV-MK38, MK38#818 and PVO.4 showed more than seven times greater neutralization resistance to 2F5 than did SHIV-KS661. sCD4 reacts with HIV-1 gp120 and inhibits viral infection. The IC 50 of PVO.4 against sCD4 exceeded 5.0 mg ml 21 , indicating that it was resistant to inhibition. The IC 50 of SHIV-MK38 against sCD4 was 1.4 mg ml
, whilst that of SHIV-KS661 was 0.1 mg ml
, indicating that the inhibition resistance of SHIV-MK38 was 14-fold greater than that of KS661. The IC 50 values of MK38#814 and MK38#818 were 0.2 and 0.6 mg ml 21 , respectively. MK38#818 showed mild inhibition resistance compared with SHIV-MK38. Taken together, these results suggested that parental highly pathogenic X4 tropic SHIV-KS661 was neutralization sensitive, similar to the tier 1 virus, but that monkey-adapted R5 tropic SHIV-MK38, which acquires the general neutralization-resistant phenotype as a clone virus, was similar to tier 2 or 3 viruses.
Sequence analysis of MK38#814 and MK38#818
As Env is the primary target for neutralizing antibodies, mutations in Env may be involved in acquiring (c) Analysis of the neutralization resistance of each virus to three kinds of anti-HIV-1 neutralizing mAbs and sCD4. After pre-incubating 100 TCID 50 of each virus and each HIV-1 neutralizing mAb or sCD4, TZM-bl cells were cultured with the mixture for 48 h, after which luciferase activity was measured. KD-247 and 2F5 were diluted fourfold from 50 to 0.012 mg ml
21
, 4E10 was diluted fourfold from 40 to 0.010 mg ml 21 and sCD4 was diluted fourfold from 5 to 0.0003 mg ml
.
Y. Ishida and others neutralization resistance. Therefore, nucleotide sequences of the env gene of MK38#814 and MK38#818 were determined and amino acid mutations were deduced. No mutation was detected in the epitopes of any of the three types of anti-HIV-1 neutralizing mAbs examined in this study or in CD4bs, indicating that those neutralization epitopes and CD4bs were retained in SHIV-MK38#814 and SHIV-MK38#818. When the amino acid sequences of MK38#814 and MK38#818 were compared with the original SHIV-KS661, there were 17 amino acid mutations, except for the five mutations for changing co-receptor usage (Table 1 ). In total, 11 of the 17 mutations were related to changes in potential N-linked glycosylation sites (PNGSs) (5/11) and/or net charges (8/11). Regarding the structural model of Env, most of the amino acid substitutions were located outside of the Env trimeric structure including the V1/V2 loop region. There were some mutations (282, 389 and 422) close to CD4bs on the three-dimensional structure (Fig. 3) . This suggested that the neutralization-resistant phenotype of SHIV-MK38 was acquired by conformational changes on the outside of the specific Env structure associated with the net charge and PNGSs retaining each neutralizing epitope.
Co-receptor use of SHIV-MK38 molecular clones
To confirm that MK38#814 and MK38#818 were R5 tropic, an assay to determine virus co-receptor tropism was performed with small-molecule inhibitors (Fig. 4) . For SIVmac239, used as a positive control for the R5 tropic virus, dose-dependent inhibition was observed in the presence of AD101 (R5 inhibitor) alone or with both AD101 and AMD3100 (X4 inhibitor). For HIV-1 NL4-3, used as a positive control for the X4 tropic virus, dose-dependent inhibition was observed in the presence of AMD3100 alone or with both AD101 and AMD3100. As the infectivity of MK38#814 and MK38#818 showed a reduction in dosedependent inhibition in the presence of AD101 alone or with both AD101 and AMD3100, the reaction curve of the molecular clones was similar to that of SIVmac239. These data indicated that MK38#814 and MK38#818 were R5 tropic.
In vitro replication in rhesus macaque PBMCs
In vitro replication competency in rhesus macaque PBMCs was assayed using MK38#814 and MK38#818 (Fig. 5) . The cultured supernatants were collected every day up to 12 days p.i., after which reverse transcriptase activity was measured. The peak reverse transcriptase activity of SHIV-MK38 was attained at 6 days p.i. at a value of 4287 c.p.m. The reverse transcriptase activities of MK38#814 and MK38#818 peaked at 7 days p.i. at 2768 and 5931 c.p.m., respectively. SIVmac239 had the highest reverse transcriptase activity at 4 days p.i. SHIV-MK1 reverse transcriptase 
GenBank accession numbers are given in parentheses. Neutralization sensitive SHIV-MK38 clone, MK38#812 (LC108990), was also registered. *Change of net charge. DChange of N-glycosylation sites. dChanging co-receptor usage.
activity was 5066 c.p.m. following the peak at 9 days p.i. Thus, the replication of SHIV-MK38#818 in rhesus PBMCs was comparable to that of parental SHIV-MK38, although the replication was slower and the peak value was lower relative to SIVmac239.
In vivo inoculation experiment involving MK38#818
Based on the above results, we determined that MK38#818 reflected the improved behaviour of the parental SHIV-MK38 strain. Therefore, to examine whether MK38#818 established a durable infection in rhesus macaques, three macaques (MM596, MM597 and MM599) were inoculated intrarectally with 10 000 TCID 50 MK38#818. The results showed that all monkeys generated peak plasma viral loads ranging from 1.6|10 7 to 2.2|10 7 copies ml 21 at 2 weeks p.i. (Fig. 6a) . MM597 maintained a set point of 10 5 copies ml 21 until 12 weeks p.i., which established a durable infection. However, the plasma viral load in MM596 was 3.9|10 2 copies ml 21 at 12 weeks p.i., decreasing to nearly below the detection limit. MM599 also had no set point and at 9 weeks p.i. the plasma viral load had decreased to below the detection limit. Therefore, these data showed that MK38#818 exhibited robust replication in MM597, but was suppressed in MM596 and MM599.
We also analysed counts of circulating CD4
+ T-lymphocytes (Fig. 6b) . None of the monkeys showed a reduction in either total or memory CD4
+ T-lymphocytes in peripheral blood.
To examine the influence of viral replication in the effector site where most memory CD4 + T-lymphocytes reside, rectal tissues were collected from all three monkeys and the percentage of CD4 + T-lymphocytes in rectal mononuclear cells was assessed (Fig. 6c) . All three monkeys showed a transient reduction in the percentage of CD4 + T-lymphocytes in rectal mononuclear cells. MM597, the monkey that was persistently infected with a high viral load, showed a decrease from 68 to 12 % over a few weeks, indicating that MK38#818 preferentially infected memory CD4 + T-lymphocytes in effector sites and caused a rapid reduction in MM597.
To examine whether antibody responses occurred in rhesus monkeys, we performed a particle agglutination assay with the plasmas at 0, 2, 4, 6, 8, 10 and 12 weeks p.i. (Table 2) . Although no antibody response was observed up to 2 weeks p.i. in MM596 and up to 4 weeks p.i. in MM597 and MM599, antibody responses were detected from 4 weeks p.i. onward in MM596 and 6 weeks p.i. onward in MM597 and MM599. Furthermore, to assess the neutralizing activity of MK38#818-infected monkey plasma, we performed a neutralization assay using plasma from each monkey obtained at 0, 6 and 12 weeks p.i. The week 12 p.i. plasma from MM597 neutralized SHIV-KS661, MK38#818 and NF462, which possessed the extremely neutralization-sensitive tier 1A reference strain HIV-1 SF162 env gene (Kawamura et al., 1994) , with ID 50 values of 1 : 33.2, 1 : 49 and 1 : 208.4, respectively ( Table 2 ). The week 6 p.i. plasma from MM597 neutralized only the extremely neutralization-sensitive NF462 and the ID 50 was 1 : 34.1. The other plasma samples did not show neutralizing activity. These results showed that MK38#818 replicated in MM597, even in the presence of the neutralizing antibody response. Fig. 3 . Model of (a) gp120 and (b) trimeric structure of Env. The model is from Protein Data Bank ID: 3J70 (Rasheed et al., 2015) and visualized by UCSF Chimera software. The mutations associated with MK38#814 and MK38#818 were fitted into the model. The parts of gp120 and gp41 are coloured in blue and cyan, respectively. The domains of V1/V2, V3 and CD4bs are highlighted in green, magenta and orange, respectively. The mutation sites associated with co-receptor switching in V3 are indicated in yellow. The mutation sites associated with PNGSs and/or net charge are indicated in red. Other mutation sites are indicated in light blue.
DISCUSSION
We previously reported that a new R5 tropic SHIV generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-89.6, was adapted to rhesus monkeys and became neutralization resistant against autologous plasma . Therefore, in this study we generated SHIV-MK38 molecular clones and examined the precise neutralization phenotype of SHIV-MK38 and its molecular clones. We found that SHIV-MK38 did not merely escape from strain-specific antibodies by accumulating variants, but acquired neutralization resistance against various antibodies as a molecular clone. As SHIV-MK38 is a derivative of SHIV-89.6, data on genetic mutations associated with the pathogenesis can be compared directly with those of SHIV-89.6P, which is the most widely used SHIV for understanding HIV-1 pathogenesis and in vaccine development. To examine how SHIV-MK38 acquired the neutralizationresistant phenotype, we analysed the sequences of the env genes of neutralization-resistant molecular clones. In addition, the mutational positions that might be associated with the acquisition of neutralization resistance were analysed based on the predicted structure. There was no direct mutation of the neutralizing epitopes, whilst there were several mutations in the V1/V2 region and outside of the Env trimeric structure which might lead to conformation changes and block access of neutralizing antibodies. To date, there have been several hypotheses regarding the mechanism for the neutralization resistance of HIV-1, i.e. a glycan shield (to prevent access of neutralizing antibodies to conserved epitopes by adding, losing and shifting PNGSs) and the amount of positive net charge (Wei et al., 2003) . As most of the mutations found in MK38#814 and MK38#818 were associated with PNGSs and net charge, these mechanisms might lead to the acquisition of the neutralization-resistant phenotype.
Why did the parental X4 tropic SHIV-KS661 maintain the neutralization-sensitive phenotype after acclimation to monkeys, although its derivative R5 tropic SHIV-MK1 became the neutralization-resistant SHIV-MK38 upon post-monkey adaptation? We suggest that the co-receptor tropism of the viruses may be associated with these observations. The remarkable difference between R5 tropic and X4 tropic viruses is in the values of V3 net Cardozo et al., 2007) . Now, we were able to shift the co-receptor use of the viruses by controlling the net positive charge of V3 (Cardozo et al., 2007) . The values for the net positive charge of V3 are generally higher in X4 tropic viruses than in R5 tropic viruses. Naganawa et al. (2008) predicted that a decrease in V3 net positive charge leads to less exposed V3 from a structural standpoint, resulting in immunological escape from neutralizing antibodies. This prediction may support the hypothesis of 'open' and 'closed' conformations of Env, which is associated with the accessibility of antibodies. Repits et al. (2008) investigated the amino acid mutations related to the change in net charge of the virus Env isolated before and after AIDS; most of the mutations related to increased net positive charge were found in variable regions, excluding V3. This suggests that X4 tropic viruses emerge only later during the course of infection and they may not reflect the 'closed' form of Env due to some conformational limitations. Thus, the difference in co-receptor tropism determined by V3 linking its net charge may determine the structural constraints of the entire Env protein structure, affecting the neutralization-resistant phenotype of the virus.
It is important to consider the extensive mutation of the HIV-1 Env during monkey-to-monkey passages as frequently used SHIVs are adapted to the monkey in order to become pathogenic (Etemad-Moghadam et al., 2000; Hsu et al., 2003; Gautam et al., 2012) . Boyd et al. (2015) reported that SHIV adapted to utilize the monkey CD4 molecule, resulting in conformational changes that exposed epitopes in the variable regions. Although the corresponding mutations associated with increased monkey CD4-mediated entry in their report were not observed in our study, there were some mutations around CD4bs and several direct mutations in the V1/V2 region which might be involved in increased monkey CD4-mediated entry.
Although SHIV-KS661 is highly pathogenic by intravenous inoculation, it is easily controlled by host immune responses when intrarectally inoculated into monkeys . In this study, we showed that the neutralization-resistant R5 tropic SHIV-MK38#818 molecular clone derived from SHIV-KS661 can cause stably persistent infection with high viral load via intrarectal inoculation despite the immune responses that occurred in the host. Currently, SHIV AD8 , categorized as a tier 2 neutralization-resistant phenotype, is widely used as a SHIV challenge virus for a variety of vaccine developments (Nishimura et al., 2010; Shingai et al., 2012 Shingai et al., 2013; Gardner et al., 2015; Francica et al., 2015) . However, use of SHIV AD8 as the only challenge virus is very risky for precise evaluation in vaccine candidates and anti-HIV-1 neutralizing antibodies. Hence, it is important to generate some challenge viruses. MK38#818 is inferior to SHIV AD8 in terms of pathogenesis. However, there is still room to improve MK38#818 because the genetically diverse SHIV-MK38 exhibited stably persistent infection with high viral load via intravenous inoculation in all three monkeys . MK38#818 was the best molecular clone of the six clones obtained in this study, but may not be the best amongst all SHIV-MK38 variations because the neutralization resistance of MK38#818 was not as strong as that of SHIV-MK38 in the assay using neutralizing mAbs. Therefore, we could select a better clone than MK38#818. It is also possible that there are unknown mechanisms, aside from the neutralization phenotype, that are related to stably persistent infection in rhesus monkeys. Mutation sites exterior to Env, for example, may be important in acquiring stable infection with high viral load in monkeys. Obtaining better clones will provide valuable information regarding the molecular basis of pathogenesis for AIDS through comparative analysis of the SHIV-89.6 lineage.
METHODS
Viruses. The stock viruses were prepared with 293T cells by transfection or with C8166-CCR5 cells by infection Seaman et al., 2010) . The titration was performed with TZM-bl cells for in vitro assays and with C8166-CCR5 cells for the in vivo inoculation experiment. The titration procedure with TZM-bl cells was performed as described previously (Otsuki et al., 2014) . The procedure involving C8166-CCR5 cells was performed by limiting dilution.
Cells. C8166-CCR5 cells (Shimizu et al., 2006) were maintained in RPMI 1640 (Invitrogen) supplemented with 10 % (v/v) FBS (HyClone Laboratories). 293T cells (DuBridge et al., 1987) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Wako Pure Chemicals) supplemented with 10 % FBS and 1 mM L-glutamine. TZM-bl cells (Platt et al., 1998) from the National Institutes of Health (NIH) AIDS research and reference reagent program were maintained in DMEM with 10 % FBS, 1 mM L-glutamine and 1 mM sodium pyruvate. PBMCs were prepared with the Ficoll density gradient separation method. For this procedure, lymphocyte separation medium 1077 for humans (Wako Pure Chemicals) was used as a separation solution. Residual red blood cells were removed using ACK lysing buffer (0.15 M NH 4 Cl, 10 mM KHCO 3 , 1.0 mM EDTA-2Na).
PBMCs were stored in a deep freezer (280 uC) or maintained in RPMI 1640 (Invitrogen) supplemented with 10 % FBS, 2 mM L-glutamine (Nacalai Tesque), 1 mM sodium pyruvate (MP Biomedicals), 50 nM 2-mercaptoethanol (Nacalai Tesque) and 40 mg gentamicin ml 21 (Nacalai Tesque).
Generation of infectious molecular clones. To construct SHIV-MK38 molecular clones, viral RNA was extracted using a QIAamp Viral RNA Mini kit (Qiagen) according to the manufacturer's protocol. cDNA including the env gene was synthesized by extracted RNA through the reverse transcriptase reaction using primer SHenv9R (59-GAGGCATATGTTAGATACCC-39) and SuperScript III FirstStrand Synthesis SuperMix (Invitrogen). Approximately 3.0 kbp of the region including the env gene from the cDNA as a template was amplified by PCR using primers SIV20F (59-CTCCAGGACTAGCA-TAAATGG-39) and . PCR was performed as follows: one cycle of denaturation (98 uC, 2 min), 45 cycles of amplification (98 uC, 10 s, 61 uC, 30 s and 68 uC, 4 min) and an additional cycle for final extension (68 uC, 7 min) using KOD FX buffer, 0.4 mM dNTP, 0.3 mM primer, 0.02 U KOD FX (TOYOBO), and a template. After the PCR product had been purified using a NucleoSpin Gel and PCR Clean-up kit (TaKaRa), 8 mg purified PCR product was reacted to digest with 10 U restriction enzymes Sph I and Xho I at 37 uC for 8 h. After electrophoresis, the 2.7 kbp band was collected from an agarose gel [0.8 % agarose S powder (Wako Pure Chemicals) and 0.5 mg ethidium bromide ml 21 in 1|TBE buffer (89 mM Tris/borate, 2 mM EDTA)] and purified. To insert purified DNA into pSHIV-KS661, pSHIV-KS661 was processed as described earlier, and the 10 kbp band was collected by agarose gel electrophoresis and purified. Using Ligation Mix (TaKaRa), env-depleted pSHIV-KS661 was reacted with the insert DNA at a ratio of 1 : 3.5. Cloning was then conducted by transforming the obtained plasmid DNA into Stbl2 cells. Six molecular clones were obtained: MK38#811, MK38#812, MK38#813, MK38#814, MK38#816 and MK38#818.
Neutralization assays. To evaluate virus neutralization resistance, we performed neutralization assays using plasma at 16 weeks p.i. from SHIV-MK38-infected monkeys, a pooled plasma of HIV-1-infected individuals (ZeptoMetrix) and anti-HIV-1 monoclonal neutralization antibodies. Luciferase activity was measured using TZM-bl cells in the assay (Wei et al., 2002) . For plasmas collected from the infected monkeys, the infectivity was defined as 100 % in the presence of week 0 p.i plasma. In the case of the pooled plasma of HIV-1-infected individuals, MK38#818-infected monkey plasma, anti-HIV-1 neutralizing mAbs and sCD4, the infectivity was defined as 100 % in the absence of the pooled plasma, mAbs or sCD4. The pooled plasma, MK38#818-infected monkey plasma, neutralizing mAbs and sCD4 were serially diluted, and ID 50 or IC 50 was determined.
At 16 weeks p.i., plasma from SHIV-MK38-infected monkey was inactivated by digesting at 56 uC for 30 min. Plasma was then diluted by 1 : 40 and pre-incubated with 100 TCID 50 virus at 37 uC for 60 min. After the reaction, 5000 TZM-bl cells were cultured with a pre-incubated mixture under 5 mg DEAE dextran ml 21 at 37 uC for 48 h. To measure luciferase activity, 50 ml culture cell lysate solution (Toyo Ink Group) was added to each well and the plate was agitated for 15 min. An aliquot of 30 ml lysate was transferred to a Nunc F96 MicroWell white plate (Thermo Scientific) and the luminescent substrate was added to each well. The luciferase activity was then calculated with Mikrowin (Berthold Technologies) using a TriStar LB 941 reader (Berthold Technologies).
For pooled plasma of HIV-1-infected individuals and MK38#818-infected monkey plasma, the plasma was diluted twofold from 1 : 50 to 1 : 3200. Subsequently, ID 50 was calculated as described earlier.
For anti-HIV-1 monoclonal neutralization antibodies, three types of anti-HIV-1 monoclonal neutralizing antibodies were used: KD-247 (which recognizes the epitope GPGR in the V3 region of gp120 and was kindly provided by the Chemo-Sero-Therapeutic Research Institute, Japan), 4E10 (which recognizes the epitope NWFDIT) and 2F5 (which recognizes the epitope ELDKWA) (both distributed by Dr Hermann Katinger through the NIH AIDS reagent program). These mAbs were diluted fourfold: KD-247 and 2F5 from 50 to 0.012 mg ml 21 and 4E10 from 40 to 0.010 mg ml
21
. IC 50 values were then calculated as described earlier.
For sCD4, sCD4 was diluted fourfold from 5.0 to 0.0003 mg ml 21 . Subsequently, the IC 50 was calculated as described above.
Inhibition of viral replication by small-molecule inhibitors. The inhibitor AD101 was kindly provided by Dr Julie Strizki (Schering Plough Research Institute, Kenilworth, NJ, USA). AMD3100 was purchased from Sigma-Aldrich. The procedure for inhibition assays was performed as described previously (Otsuki et al., 2014) . Inhibitors were diluted threefold from 4 to 0.005 mM in this study.
In vitro replication of the viruses in PBMCs. PBMCs were isolated from a non-infected monkey and cultured with medium, adding 10 % (v/v) FBS, 2 mM L-glutamine (Nacalai Tesque) and 1 mM sodium pyruvate (MP Biomedicals). PBMCs were stimulated with concanavalin A (25 mg ml
; Sigma-Aldrich) on day 1, after which the cells were cultured with human recombinant IL-2 (160 U ml 21 ; Wako Pure Chemicals). After 3 days, stimulated PBMCs were spinoculated with each virus at m.o.i. 0.1 at 1200 g for 60 min to achieve efficient infection (O'Doherty et al., 2000) . The supernatants in cultured cells were collected for up to 12 days and the reverse transcriptase activity in each supernatant was measured.
Sequencing analysis. Nucleic acid sequences of MK38#814 and MK38#818 in plasmid DNA were determined with the Big Dye Terminator version 3.1 cycle sequencing kit (Applied Biosystems). The reaction conditions were as follows: one cycle of 96 uC for 2 min, followed by 25 cycles of 96 uC for 10 s, 50 uC for 5 s, and 60 uC for 4 min. The PCR product was purified with CleanSEQ (Beckman Coulter) and analysed using an ABI Prism 3130 Genetic Analyzer (Applied Biosystems).
Virus inoculation. Indian-origin rhesus macaques were used in accordance with the institutional regulations approved by the Committee for Experimental Use of Non-human Primates of the Institute for Virus Research, Kyoto University, Kyoto, Japan. Monkeys were housed in a Biosafety Level 3 facility and all procedures were performed in this facility. Blood collection, rectal biopsy and virus intrarectal inoculation (10 000 TCID 50 MK38#818) were performed under ketamine hydrochloride (Daiichi Sankyo). The virus was inoculated into the anus as previously described and then stood for 30 min (Miyake et al., 2006) . The plasma viral load was measured by quantitative reverse transcription PCR as reported previously (Miyake et al., 2006) . The detection limit was 200 copies ml 21 .
Rectal biopsy. In total, 10 pieces of rectal tissue were collected using biopsy forceps (Olympus). Rectal tissue was washed with MACS buffer (Miltenyi Biotec) and then incubated in pre-incubation buffer [1 % BSA, 10 mM HEPES (Nacalai Tesque), 1 mM DTT (SigmaAldrich) in Hanks' balanced salt solution (HBSS; Nacalai Tesque)] at 37 uC for 30 min with mild shaking. Rectal tissue was washed with MACS buffer and then with 10 mM HEPES in HBSS. Rectal tissue was then digested using a Lamina Propria Dissociation kit (Miltenyi Biotec) in a C tube (Miltenyi Biotec) at 37 uC for 30 min using the m_brain_01_01 program of a gentleMACS Octo Dissociator (Miltenyi Biotec). Rectal tissue was then processed using the m_in-testine_01 program of a gentleMACS Octo Dissociator (Miltenyi Biotec). Rectal mononuclear cells were collected through a 70 mm strainer (BD PharMingen). (Pitcher et al., 2002) , wholeblood and rectal samples were stained with seven fluorescent antibodies: Pacific Blue-conjugated anti-human CD3 antibody (clone SP34-2; BD PharMingen), PerCP-Cy5.5-conjugated anti-human CD4 antibody (clone L200; BD PharMingen), allophycocyanin (APC)-Cy7-conjugated anti-human CD8 antibody (clone SK1; BD PharMingen), FITC-conjugated anti-human CD20 antibody (clone L27; BD PharMingen), phycoerythrin-conjugated anti-human CD28 antibody (clone CD28.2; BD PharMingen) and APC-conjugated antihuman CD95 (clone DX2; BD PharMingen). Whole-blood and rectal samples were reacted with lysing solution (BD BioScience) for 10 min to lyse red blood cells. Each sample was then analysed with a FACSCanto II analyser (BD BioScience). The absolute numbers of total CD4
+ T-lymphocytes, naive CD4 + T-lymphocytes and memory CD4 + T-lymphocytes in peripheral blood were calculated using a KX-21 analyser (Sysmex).
Determination of antibody titres. Anti-HIV antibody titres were determined using a commercial particle agglutination kit (Serodia-HIV1/2; Fujirebio). Isolated plasma samples were serially diluted and assayed as described previously . The end-point of the highest dilution giving a positive result was determined to be the titre.
